Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1 study of ABBV-400 in advanced solid tumors
jRCT2031210395Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telisotuzumab adizutecan in advanced nonhematological malignancy, non-small cell lung cancer (NSCLC), gastroesophageal junction adenocarcinoma and 2 more (12 arms), sponsored by AbbVie Inc. Primary endpoint: Objective Response Rate. Started Dec 2021; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
advanced nonhematological malignancynon-small cell lung cancer (NSCLC)gastroesophageal junction adenocarcinomacolorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210395.